BIOS:NSD-Option Care Health, Inc (USD)

COMMON STOCK | Other | NSD

Last Closing Price

USD 11.90

Change

0.00 (0.00)%

Market Cap

USD 2.95B

Volume

0.04M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Option Care Health, Inc. provides independent home and alternate site infusion services in the United States. It serves patients with acute and chronic conditions. The company is based in Bannockburn, Illinois.

Company Website : http://www.bioscrip.com

Address : 1600 Broadway, Suite 700 80202,Denver,USA

Employees : 3,869

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.19

52 Week High : 14.90

52 Week Low : 11.15

200 Day Moving Average : 14.00

50 Day Moving Average : 9.55

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-03 )

Largest Industry Peers for Other

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
LGCY Legacy Reserves Inc

N/A

 USD61,525,874.67B 1.10 5.30
FTD FTD Companies, Inc

N/A

 USD28,725,913.80B N/A N/A
KEYW The KeyW Holding Corporation

N/A

 USD24,651,104.38B 166.80 24.48
SNHY Helios Technologies, Inc

N/A

 USD17,848,852.22B 1,000,000.00 N/A
QTNA Quantenna Communications, Inc

N/A

 USD8,997,243.52B 175.07 79.98
INSY INSYS Therapeutics, Inc

N/A

 USD4,995,459.82B 115.90 N/A
CHKE Apex Global Brands Inc

N/A

 USD384,202.91B 17.30 N/A
AMCN AirNet Technology Inc

N/A

 USD308,457.30B 1.00 N/A
PDVW pdvWireless, Inc

N/A

 USD95,944.74B N/A N/A
AIPT Predictive Oncology Inc

N/A

 USD38,513.36B N/A N/A

ETFs Containing BIOS

Symbol Name Weight Mer Price(Change) Market Cap
XHS SPDR Series Trust - SPDR .. 0.00 % 0.35 %

+1.11 (+0.99%)

 USD0.21B

Market Performance

  Market Performance vs.
Industry/Classification (Other)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -15.00% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.00% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 357.69% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 357.69% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 92.75% N/A N/A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 92.75% N/A N/A 95% A
Risk Return Profile  
Volatility (Standard Deviation) 133.11% N/A N/A 7% F
Risk Adjusted Return 69.68% N/A N/A 72% C-
Market Capitalization 2.95B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Other)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.39 N/A N/A N/A N/A
Price / Cash Flow Ratio 74.81 N/A N/A N/A N/A
EV/EBITDA 58.76 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 0.15% N/A N/A N/A N/A
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio 140.85% N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.19 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike